We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CSL:ASXCSL Limited Analysis

Data as of 2026-07-31 - not real-time

A$123.06

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

CSL Limited is trading above its short‑ and medium‑term moving averages while remaining below its long‑term average, suggesting a short‑term upside within a broader downtrend. The relative strength index sits in a neutral zone and the MACD has turned bullish, reinforcing a modest technical bias to the upside. However, the stock is experiencing a pronounced price decline of more than half over the past year and a substantial year‑to‑date drop, reflecting eroded market confidence. Volatility is elevated, yet the beta is exceptionally low, indicating that price swings are largely company‑specific rather than market‑driven. Fundamentals show a price‑to‑earnings multiple far below the industry average and a discounted cash‑flow model that points to a meaningful upside potential, while the dividend yield remains attractive with a payout ratio well under half of earnings. The balance sheet carries considerable debt relative to equity, but cash flow generation and a solid dividend policy suggest the dividend is sustainable. Analyst sentiment remains positive, with a consensus rating of buy, implying that many view the current price as a buying opportunity despite recent weakness.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price near resistance with limited upside in the near term
  • elevated short‑term volatility
  • recent sharp sell‑off eroding momentum

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • valuation gap versus peers and DCF upside
  • attractive dividend yield and sustainable payout
  • technical indicators turning bullish

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • low beta reducing systematic risk
  • strong cash flow and dividend sustainability
  • global diversification across therapeutic segments

Key Metrics & Analysis

Financial Health

Revenue Growth-1.80%
Profit Margin9.06%
P/E Ratio13.9
ROE6.66%
ROA6.58%
Debt/Equity54.44
P/B Ratio2.2
Op. Cash FlowA$3.6B
Free Cash FlowA$1.8B
Industry P/E29.4

Technical Analysis

TrendNeutral
RSI55.8
SupportA$113.75
ResistanceA$128.99
MA 20A$121.96
MA 50A$112.36
MA 200A$148.00
MACDBullish
VolumeStable
Fear & Greed Index91.54

Valuation

Fair ValueA$28.66
Target PriceA$138.88
Upside/Downside12.85%
GradeUndervalued
TypeValue
Dividend Yield3.46%

Risk Assessment

Beta0.01
Volatility36.30%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.